AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2018

Jan 25, 2018

SEC Form 4/A — Form 4/A

Issuer: AGIOS PHARMACEUTICALS INC (AGIO)
CIK: 0001439222
Period of Report: 2017-12-01

Reporting Person: Schenkein David P (Director, Chief Executive Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-12-01	Stock option (right to buy)	$0.3025	M	6000	Disposed	2019-08-12	Common stock (6000)	Direct

Footnotes

F1: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: This option was granted on August 13, 2009. The shares underlying this option vest as to 25% of the shares on August 1, 2010, with the remaining 75% vesting in 36 equal monthly installments thereafter.

F3: The original Form 4, filed on December 5, 2017, is being amended by this Form 4 amendment solely to correct the number of derivative securities beneficially owned following reported transaction.